leased mainly through industrial practices, including the burning of fossil fuels and solid wastes. It is the inorganic forms of mercury (for example, elemental mercury and mercuric chloride) that are released from coal-fired power plants, not the organic form of mercury or methylmercury. The inorganic forms of mercury are released from industrial pollution and then eventually are deposited into surface water, accumulating in streams and oceans. Bacteria in the water cause chemical changes that transform the inorganic forms of mercury into methylmercury. It is this organic form of mercury that accumulates in fish and can be toxic. Fish absorb methylmercury from water and their food as they feed on aquatic organisms. Larger, predatory fish accumulate higher concentrations of methylmercury (3, 8) .
Fifth, the levels of polychlorinated biphenyls (PCBs) reported in Fisher Wilson's article for farm-raised salmon-30 parts per billion or 0.030 parts per million (ppm) or 0.03 mg/kg-are very low. At this level, the Great Lakes, Connecticut, North Carolina, and other states would not issue a fish consumption advisory. When EPA standard equations are used and a 50% loss from cooking is assumed, a person can safely eat 4 meals per week, which is calculated as follows Eating 4 meals per week of only farm-raised salmon would be safe, and the PCB exposure dose would be equal to the EPA's recommended dose of 0.00002 mg/kg-d. The cancer risk at this recommended meal limit of 4 meals per week of salmon with average PCB levels of 0.030 ppm would correlate to an excess cancer risk of approximately 1 in 25 000, which is within the EPA target risk range of 1 in 10 000 to 1 in 1 million. The cancer risk can be calculated as shown (9, 10): 2.0 risk per mg/kg-d ϫ 0.00002 mg/kg-d ϭ 4/100 000, or approximately 1 out of 25 000
Women of childbearing age and children can safely eat up to 2 meals per week of fish low in PCBs and methylmercury. Eating 2 meals per week of these fish is both safe and healthy. 
TO THE EDITOR:
In general, the recent Current Clinical Issues article on the risks and benefits of fish consumption (1) was informative and useful to physicians trying to understand the issues facing their fish-consuming patients. However, as a member of the former National Academy of Sciences/National Research Council committee responsible for the recommendations for exposure to methylmercury referenced in the article, I believe it is necessary to clarify some information regarding the risk to patients with elevated levels of methylmercury.
The article states that "Many Americans are believed to have dangerous levels of methylmercury in their bodies. . . .Levels higher than 5 g/L in blood or higher than 1 g/g in hair are potentially hazardous to a developing fetus. . . .This level corresponds to a reference dose of approximately 0.1 g/kg of body weight per day of methylmercury exposure." This reference dose is, in fact, specifically defined by the EPA as "an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime" (2). Thus, exposure at the reference dose, and the related blood and hair concentrations of mercury, corresponds to a virtual safe level of exposure. Exposure exceeding this dose exceeds this safety benchmark but does not necessarily imply "danger." In general, patients who moderately exceed this benchmark, particularly pregnant women and women planning to become pregnant, should be encouraged to reduce their exposure by substituting high-mercury fish in their diets with fish whose mercury levels are characteristically lower. The reference dose is a useful warning sign of elevated exposure and a prompt for prudent modification of a patient's diet. However, the reference dose should not be interpreted as a bright-line indication of clinical "danger" leading to drastic action on the part of either the physician or the patient. renal failure occurred in early trials (2) . We report on a patient who developed rhabdomyolysis with cardiac involvement and renal failure while taking rosuvastatin.
Case Report: A 67-year-old woman with no history of renal disease was referred with chest pain from an outside institution. She had a history of hypertension, chronic back pain, and hypercholesterolemia and was taking hydrochlorothiazide-olmesartan and oxaprozin. She had been taking rosuvastatin, 10 mg/d, for 9 months; the dose had recently been increased to 20 mg/d with the addition of fenofibrate, 160 mg/d. Two weeks before admission, the patient reported shoulder and chest pains, along with aches in the thigh. A cardiac nuclear perfusion study showed a normal ejection fraction. On the day of admission to our institution, the patient was first transported by ambulance to a local hospital reporting chest discomfort. Cardiac catheterization showed no significant coronary artery disease, a right coronary artery arising from the left coronary cusp, and an ejection fraction of 0.1 with apical dilatation and good contraction of the base, suggestive of an apical ballooning syndrome. The patient had a markedly elevated creatine kinase level (19 000 U/L). She was transferred to our institution for further care.
At our hospital, dopamine and norepinephrine were initially required for blood pressure support. An echocardiogram revealed an ejection fraction of 0.25 with an aneurysmal apex. The Table summarizes clinically significant laboratory findings. Urinalysis showed more than 100 erythrocytes per high-power field and 1 to 3 renal epithelial cells with a urine myoglobin level of 0.069 g/mL (Ͻ0.025 g/mL) and proteinuria. Results of a heart biopsy were normal. Before hospital discharge, functional cardiac magnetic resonance imaging revealed an ejection fraction of 0.47 and no perfusion defects. The patient's laboratory values and symptoms progressively improved throughout her hospital stay.
Discussion: Although initially critically ill, our patient recovered with supportive therapy and did not require a balloon pump, ventricular assist device, or hemodialysis. To our knowledge, acute cardiac decompensation with a markedly reduced ejection fraction in the setting of an angiogram negative for coronary artery disease and normal results on right ventricular biopsy has not been previously associated with rosuvastatin. We suspect this incident was either a continuation of the patient's profound myopathy or a consequence of her severe illness. The cause of transient left ventricular apical ballooning syndrome is unknown but seems to be associated with severe emotional or physiologic stress (3).
Our patient's renal failure was probably due to rhabdomyolysis, possibly exacerbated by ischemic acute tubular necrosis due to shock. Mild, poorly defined renal abnormalities (including proteinuria and microscopic hematuria) have been associated with rosuvastatin, particularly at higher doses, as seen in our patient. Fenofibrate is a mild to moderate inhibitor of CYP2C9, and this drug-drug interaction probably contributed to the presumed toxicity of rosuvastatin reported here.
Statin-related side effects involving muscle injury can range from muscular pain to rhabdomyolysis. Cardiac involvement in drug-induced rhabdomyolysis has been reported with propofol and other drugs, including heroin and cocaine (4). Punukollu and colleagues (5) reviewed 91 consecutive patients with rhabdomyolysis and found that 19 (21%) had positive cardiac troponin I values.
Conclusions:
Further study is needed to determine whether rosuvastatin has unique cardiac toxicity. Furthermore, additional data are necessary to more clearly define the risks of rosuvastatin, particularly with respect to a possible increased risk for rhabdomyolysis compared with other available statins. Certainly, careful monitoring for adverse effects, such as rhabdomyolysis and acute renal failure, is warranted in all patients treated with this statin. 
